Literature DB >> 9618576

Pentavalent rhenium-188 dimercaptosuccinic acid for targeted radiotherapy: synthesis and preliminary animal and human studies.

P J Blower1, A S Lam, M J O'Doherty, A G Kettle, A J Coakley, F F Knapp.   

Abstract

Pentavalent rhenium-188 dimercaptosuccinic acid [188Re(V)DMSA] is a beta-emitting analogue of 99mTc(V)DMSA, a tracer that is taken up in a variety of tumours and bone metastases. The aim of this study was to develop the kit-based synthesis of the agent on a therapeutic scale, to assess its stability in vivo, and to obtain preliminary biodistribution and dosimetry estimates, prior to evaluation of its potential as a targeted radiotherapy agent. The organ distribution of 188Re in mice was determined 2 h after injection of 3 MBq 188Re(V)DMSA prepared from eluate from a 188W/188Re generator. Three patients with cancer of the prostate and three with cancer of the bronchus, all with bone metastases confirmed with a standard 99mTc-hydroxymethylene diphosphonate (99mTc-HDP) scan, were given 370 MBq 188Re(V)DMSA and imaged at 3 h and 24 h using the 155-keV gamma-photon (15%). Blood and urine samples were collected to determine clearance and to analyse the speciation of 188Re. Organ residence times were estimated from the scans, and used to estimate radiation doses using MIRDOSE 3. In mice, 188Re(V)DMSA was selective for bone and kidney. In patients, it showed selectivity for bone metastases (particularly those from prostate carcinoma) and kidney, but uptake in normal bone was not significantly greater than in surrounding soft tissues. Of the normal tissues the kidneys received the highest radiation dose (0.5-1.3 mGy/MBq). The images were strongly reminiscent of 99mTc(V)DMSA scans in similar patients. High-performance liquid chromatography analysis of blood and urine showed no evidence of 188Re in any chemical form other than 188Re(V)DMSA up to 24 h. In conclusion, 188Re(V)DMSA and its 186Re analogue warrant further clinical assessment as generator/kit-derived agents for treatment of painful bone metastases. These agents should also be assessed in medullary thyroid carcinoma and other soft tissue tumours which have been shown to accumulate 99mTc(V)DMSA.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9618576     DOI: 10.1007/s002590050263

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  6 in total

Review 1.  Nuclear imaging of molecular processes in cancer.

Authors:  Rafael Torres Martin de Rosales; Erik Arstad; Philip J Blower
Journal:  Target Oncol       Date:  2009-09-25       Impact factor: 4.493

2.  99mTc/188Re-labelled lipid nanocapsules as promising radiotracers for imaging and therapy: formulation and biodistribution.

Authors:  Sandrine Ballot; Nicolas Noiret; François Hindré; Benoît Denizot; Etienne Garin; Holisoa Rajerison; Jean-Pierre Benoit
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-02-01       Impact factor: 9.236

3.  [Diagnostic value of pentavalent 99mTc-dimercaptosuccinicacid ([V]-DMSA) in head and neck tumors].

Authors:  R An; H Bender; S Guhlke; H J Biersack
Journal:  J Tongji Med Univ       Date:  2000

4.  Rhenium-188 production in hospitals, by w-188/re-188 generator, for easy use in radionuclide therapy.

Authors:  Maria Argyrou; Alexia Valassi; Maria Andreou; Maria Lyra
Journal:  Int J Mol Imaging       Date:  2013-04-09

5.  Opportunities and challenges for metal chemistry in molecular imaging: from gamma camera imaging to PET and multimodality imaging.

Authors:  Richard Southworth; Rafael Torres Martin de Rosales; Levente K Meszaros; Michelle T Ma; Gregory E D Mullen; Gilbert Fruhwirth; Jennifer D Young; Cinzia Imberti; Julia Bagunya-Torres; Erica Andreozzi; Philip J Blower
Journal:  Adv Inorg Chem       Date:  2015-11-16       Impact factor: 3.282

Review 6.  Radionuclides in the management of thyroid cancer.

Authors:  J R Buscombe
Journal:  Cancer Imaging       Date:  2007-12-17       Impact factor: 3.909

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.